



**RNS: RELEASE**

**5 June 2024**

**Immupharma PLC**  
("Immupharma" or the "Company")

**Notice of AGM & Annual Report & Accounts**

Immupharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company's Annual General Meeting ("AGM") will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG.

The Notice of AGM setting out details of the resolutions, together with the Company's Annual Report and Accounts for the year ended 31 December 2023, has been posted to those shareholders requesting a postal copy; and for other shareholders, these documents will shortly be available to view and download on the Company's website: [www.immupharma.co.uk](http://www.immupharma.co.uk).

Ends

For further information please contact:

<b>Immupharma PLC</b> ( <a href="http://www.immupharma.co.uk">www.immupharma.co.uk</a> )	+ 44 (0) 207 206 2650
Tim McCarthy, Chairman and Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
<b>SPARK Advisory Partners Limited (NOMAD)</b>	+44 (0) 203 368 3550
Neil Baldwin	
<b>Stanford Capital Partners (Joint Broker)</b>	+44 (0) 203 815 8880
Patrick Claridge, Bob Pountney	
<b>SI Capital (Joint Broker)</b>	+44 (0) 1483 413500
Nick Emerson	

**Notes to Editors**

**About Immupharma PLC**

Immupharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.

For additional information about Immupharma please visit: [www.immupharma.co.uk](http://www.immupharma.co.uk)

Immupharma's LEI (Legal Entity Identifier) code : 213800VZKGHC7VUS895.

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSLELFBZQLEBBK